{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:42:16Z","timestamp":1772804536405,"version":"3.50.1"},"reference-count":121,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1016\/j.leukres.2003.08.017","type":"journal-article","created":{"date-parts":[[2003,11,15]],"date-time":"2003-11-15T12:00:40Z","timestamp":1068897640000},"page":"429-442","source":"Crossref","is-referenced-by-count":41,"title":["Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era"],"prefix":"10.1016","volume":"28","author":[{"given":"Chadi","family":"Nabhan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald B","family":"Gartenhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin S","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2003.08.017_BIB1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3322\/canjclin.51.1.15","article-title":"Cancer statistics 2001","volume":"51","author":"Greenlee","year":"2001","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.leukres.2003.08.017_BIB2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB3","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2003.08.017_BIB4","first-page":"41","article-title":"A phase I and II study of pentostatin (Nipent) with cyclophosphamide for previously treated patients with chronic lymphocytic leukemia","volume":"27","author":"Weiss","year":"2000","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB5","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V92.4.1165","article-title":"Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy","volume":"92","author":"Keating","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB6","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1200\/JCO.2001.19.5.1414","article-title":"Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia","volume":"19","author":"O\u2019Brien","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB7","first-page":"3","article-title":"Metabolism and action of fludarabine phosphate","volume":"17","author":"Plunkett","year":"1990","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB8","unstructured":"Cass C. Nucleoside Transport. In: Georgopapakakou N, editor. Drug Transport in Antimicrobial and Anticancer Chemotherapy. New York: Marcel Dekker, 1994."},{"key":"10.1016\/j.leukres.2003.08.017_BIB9","doi-asserted-by":"crossref","first-page":"9732","DOI":"10.1016\/S0021-9258(19)38732-0","article-title":"Nucleoside transport in L1210 murine leukemia cells. Evidence for three transporters","volume":"265","author":"Crawford","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.leukres.2003.08.017_BIB10","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1182\/blood-2002-07-2236","article-title":"Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia","volume":"101","author":"Molina-Arcas","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB11","unstructured":"W Plunkett VG. Cellular metabolism of nucleoside analogues in CLL. In: Cheson B, editor. implications for drug development in chronic lymphocytic leukemia: scientific advances and clinical developments. New York: Marcel Dekker, 1993."},{"key":"10.1016\/j.leukres.2003.08.017_BIB12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/10428199309147356","article-title":"Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy","volume":"10","author":"Gandhi","year":"1993","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2003.08.017_BIB13","first-page":"653","article-title":"Pharmacokinetics of cladribine in plasma and its 5\u2032-monophosphate and 5\u2032-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia","volume":"4","author":"Albertioni","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2003.08.017_BIB14","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/sj.leu.2401845","article-title":"Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine","volume":"14","author":"Huang","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2003.08.017_BIB15","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580","article-title":"p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias","volume":"85","author":"Dohner","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF01575446","article-title":"The induction of p53 and WAF1\/CIP1 in chronic lymphocytic leukemia cells treated with 2-chlorodeoxyadenosine","volume":"74","author":"Gartenhaus","year":"1996","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.leukres.2003.08.017_BIB17","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1021\/jm00303a605","article-title":"Nucleosides of 2-fluoroadenine","volume":"12","author":"Montogomery","year":"1969","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.leukres.2003.08.017_BIB18","first-page":"18","article-title":"Pharmacokinetics of 2-F-ara-A (9-beta-d-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate","volume":"17","author":"Malspeis","year":"1990","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB19","first-page":"445","article-title":"Disposition of 9-beta-d-arabinofuranosyl-2-fluoroadenine 5\u2032-phosphate in mice and dogs","volume":"67","author":"Noker","year":"1983","journal-title":"Cancer Treat Rep."},{"key":"10.1016\/j.leukres.2003.08.017_BIB20","first-page":"104","article-title":"Specificity of systems mediating transport of adenosine, 9-beta-d-arabinofuranosyl-2-fluoroadenine, and other purine nucleoside analogues in L1210 cells","volume":"43","author":"Sirotnak","year":"1983","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2003.08.017_BIB21","first-page":"2349","article-title":"Comparison of the toxicity and metabolism of 9-beta-d-arabinofuranosyl-2-fluoroadenine and 9-beta-d-arabinofuranosyladenine in human lymphoblastoid cells","volume":"40","author":"Plunkett","year":"1980","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2003.08.017_BIB22","first-page":"2587","article-title":"Metabolism and therapeutic efficacy of 9-beta-d-arabinofuranosyl-2-fluoroadenine against murine leukemia P388","volume":"42","author":"Avramis","year":"1982","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2003.08.017_BIB23","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1200\/JCO.2001.19.22.4252","article-title":"Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia","volume":"19","author":"Boogaerts","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood.V74.1.19.bloodjournal74119","article-title":"Fludarabine: a new agent with major activity against chronic lymphocytic leukemia","volume":"74","author":"Keating","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB25","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3109\/10428199609093445","article-title":"Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience","volume":"21","author":"Montserrat","year":"1996","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2003.08.017_BIB26","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1200\/JCO.1997.15.2.458","article-title":"Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report","volume":"15","author":"Sorensen","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB27","first-page":"28","article-title":"Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin\u2019s lymphomas: a phase II study of the German Low-grade non-Hodgkin\u2019s lymphoma Study Group","volume":"20","author":"Hiddemann","year":"1993","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB28","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/oxfordjournals.annonc.a058515","article-title":"Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia","volume":"4","author":"Bergmann","year":"1993","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB29","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(96)91681-5","article-title":"Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL","volume":"347","author":"Johnson","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2003.08.017_BIB30","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V98.8.2319","article-title":"Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients","volume":"98","author":"Leporrier","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/10428190009057630","article-title":"Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia","volume":"37","author":"Keating","year":"2000","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2003.08.017_BIB32","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1182\/blood.V82.6.1695.1695","article-title":"Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment","volume":"82","author":"O\u2019Brien","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB33","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2141.1994.tb04932.x","article-title":"Late listeriosis after fludarabine plus prednisone treatment","volume":"87","author":"Girmenia","year":"1994","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB34","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1023\/A:1008228709612","article-title":"Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin\u2019s lymphoma","volume":"8","author":"Zinzani","year":"1997","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/(SICI)1099-1069(199702)15:1<27::AID-HON594>3.0.CO;2-C","article-title":"A new effective treatment for indolent lymphoma: a pilot study with fludarabine, idarubicin and prednisone combination (FLIDA)","volume":"15","author":"Caracciolo","year":"1997","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB36","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood.V94.8.2836.420k35_2836_2843","article-title":"In vitro evaluation of fludarabine in combination with cyclophosphamide and\/or mitoxantrone in B-cell chronic lymphocytic leukemia","volume":"94","author":"Bellosillo","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB37","first-page":"560","article-title":"The in vitro cytotoxic effect of mitoxantrone in combination with fludarabine or pentostatin in B-cell chronic lymphocytic leukemia","volume":"82","author":"Morabito","year":"1997","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2003.08.017_BIB38","first-page":"1290","article-title":"Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia","volume":"8","author":"Weiss","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2003.08.017_BIB39","first-page":"361","article-title":"A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study","volume":"7","author":"Elias","year":"1993","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2003.08.017_BIB40","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/BF00686108","article-title":"Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology","volume":"34","author":"Gandhi","year":"1994","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB41","first-page":"943","article-title":"Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia","volume":"9","author":"Robertson","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2003.08.017_BIB42","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3109\/10428199709051784","article-title":"Loxoribine affects fludarabine activity on freshly isolated B-chronic lymphocytic leukemia cells","volume":"26","author":"Tosi","year":"1997","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2003.08.017_BIB43","first-page":"794","article-title":"In vitro study of the combination gemcitabine + fludarabine on freshly isolated chronic lymphocytic leukemia cells","volume":"84","author":"Tosi","year":"1999","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2003.08.017_BIB44","first-page":"1268","article-title":"Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy","volume":"85","author":"Marotta","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2003.08.017_BIB45","first-page":"926","article-title":"Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients","volume":"87","author":"Mauro","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2003.08.017_BIB46","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.V96.1.71","article-title":"Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies","volume":"96","author":"Flinn","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB47","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1046\/j.1365-2141.2001.02959.x","article-title":"Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group","volume":"114","author":"Hallek","year":"2001","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB48","first-page":"515a","article-title":"Oral fludarabine and cyclophosphamide in previously untreated chronic lymphocytic leukemia: preliminary data","volume":"96","author":"Cazin","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB49","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1172\/JCI111710","article-title":"Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes","volume":"75","author":"Seto","year":"1985","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.leukres.2003.08.017_BIB50","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1021\/bi00216a032","article-title":"Effects of 2-chloro-2\u2032-deoxyadenosine 5\u2032-triphosphate on DNA synthesis in vitro by purified bacterial and viral DNA polymerases","volume":"30","author":"Hentosh","year":"1991","journal-title":"Biochemistry"},{"key":"10.1016\/j.leukres.2003.08.017_BIB51","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1073\/pnas.81.7.2232","article-title":"Antileukemic and immunosuppressive activity of 2-chloro-2\u2032-deoxyadenosine","volume":"81","author":"Carson","year":"1984","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.leukres.2003.08.017_BIB52","first-page":"1235","article-title":"Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia","volume":"54","author":"Kearns","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2003.08.017_BIB53","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1200\/JCO.1993.11.4.679","article-title":"High complete remission rate from 2-chloro-2\u2032-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count","volume":"11","author":"Juliusson","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB54","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/oxfordjournals.annonc.a010604","article-title":"Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia","volume":"7","author":"Juliusson","year":"1996","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB55","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1200\/JCO.1995.13.4.983","article-title":"Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia","volume":"13","author":"Tallman","year":"1995","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 2","key":"10.1016\/j.leukres.2003.08.017_BIB56","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/10428199309064270","article-title":"2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia and chronic lymphocytic leukemia","volume":"11","author":"Saven","year":"1993","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2003.08.017_BIB57","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJM199402033300504","article-title":"Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy","volume":"330","author":"O\u2019Brien","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2003.08.017_BIB58","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/sj.leu.2402752","article-title":"A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211","volume":"17","author":"Byrd","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2003.08.017_BIB59","first-page":"1674","article-title":"Intracellular pharmacokinetics of 2-chlorodeoxyadenosine in leukemia cells from patients with chronic lymphocytic leukemia","volume":"9","author":"Alessi-Severini","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2003.08.017_BIB60","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1200\/JCO.1996.14.7.2160","article-title":"Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia","volume":"14","author":"Juliusson","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB61","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1995.13.3.570","article-title":"2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia","volume":"13","author":"Saven","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB62","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/sj.leu.2401368","article-title":"2-Chlorodeoxyadenosine (cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger","volume":"13","author":"Robak","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2003.08.017_BIB63","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/10428199909083391","article-title":"2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia","volume":"34","author":"Robak","year":"1999","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2003.08.017_BIB64","first-page":"1875","article-title":"Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-beta-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro","volume":"9","author":"Begleiter","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2003.08.017_BIB65","first-page":"224","article-title":"2-Chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features","volume":"81","author":"Morabito","year":"1996","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2003.08.017_BIB66","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/00000421-199910000-00018","article-title":"Phase II study of 2-chlorodeoxyadenosine in combination with chlorambucil in previously untreated B-cell chronic lymphocytic leukemia","volume":"22","author":"Tefferi","year":"1999","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB67","first-page":"2723","article-title":"Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial","volume":"96","author":"Robak","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB68","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1046\/j.1365-2141.2000.01850.x","article-title":"Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia\u2014updated results of the multicentre study of 378 patients","volume":"108","author":"Robak","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB69","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/sj.leu.2402172","article-title":"A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemia","volume":"15","author":"Tefferi","year":"2001","journal-title":"Leukemia"},{"issue":"Pt B","key":"10.1016\/j.leukres.2003.08.017_BIB70","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-1-4757-0390-0_63","article-title":"Deoxyadenosine induced G1 phase arrest in leukemic T cells","volume":"165","author":"Fox","year":"1984","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB71","doi-asserted-by":"crossref","first-page":"6865","DOI":"10.1073\/pnas.77.11.6865","article-title":"Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo","volume":"77","author":"Carson","year":"1980","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.leukres.2003.08.017_BIB72","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood.V58.1.91.91","article-title":"Clinical pharmacology of deoxycoformycin","volume":"58","author":"Major","year":"1981","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB73","first-page":"4508","article-title":"Levels of 2\u2032-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemia","volume":"41","author":"Venner","year":"1981","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2003.08.017_BIB74","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF00258479","article-title":"Deoxycoformycin: neurological toxicity","volume":"5","author":"Major","year":"1981","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB75","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/jnci\/82.17.1416","article-title":"Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer","volume":"82","author":"Ho","year":"1990","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.leukres.2003.08.017_BIB76","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1989.7.4.433","article-title":"Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B","volume":"7","author":"Dillman","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB77","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1200\/JCO.1985.3.9.1196","article-title":"Low-dose deoxycoformycin in lymphoid malignancy","volume":"3","author":"Grever","year":"1985","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB78","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jnci\/85.8.658","article-title":"Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group","volume":"85","author":"Dohner","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.leukres.2003.08.017_BIB79","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1200\/JCO.2003.08.100","article-title":"Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia","volume":"21","author":"Weiss","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB80","first-page":"44","article-title":"Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia","volume":"27","author":"Waselenko","year":"2000","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB81","first-page":"3147","article-title":"Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen","volume":"40","author":"Nadler","year":"1980","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2003.08.017_BIB82","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-111-7-592","article-title":"Monoclonal antibodies for treating cancer","volume":"111","author":"Dillman","year":"1989","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.leukres.2003.08.017_BIB83","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin\u2019s lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB84","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20m","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB85","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB86","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1600-0609.1999.tb01725.x","article-title":"IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin\u2019s lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients","volume":"62","author":"Nguyen","year":"1999","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB87","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3816\/CLM.2000.n.015","article-title":"Rituximab therapy of B-cell neoplasms","volume":"1","author":"Petryk","year":"2000","journal-title":"Clin. Lymphoma"},{"key":"10.1016\/j.leukres.2003.08.017_BIB88","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2002-06-1639","article-title":"Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance","volume":"101","author":"Manshouri","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB89","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2002-03-0972","article-title":"Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia","volume":"100","author":"Schulz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB90","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB91","first-page":"3580","article-title":"DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine","volume":"7","author":"Yamauchi","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2003.08.017_BIB92","first-page":"633a","article-title":"Update of results of the combination of fludarabine, cyclophosphamide, and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL)","volume":"98","author":"Manero","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB93","first-page":"771a","article-title":"Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia","volume":"98","author":"Wierda","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB94","first-page":"25","article-title":"Pentostatin and rituximab in the treatment of patients with B-cell malignancies","volume":"14","author":"Drapkin","year":"2000","journal-title":"Oncology (Huntingt)"},{"key":"10.1016\/j.leukres.2003.08.017_BIB95","first-page":"754a","article-title":"Rituximab\/cyclophosphamide\/dexamethasone combination highly effective in autoimmune hemolytic anemia associated with chronic lymphocytic leukemia","volume":"96","author":"Rai","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB96","first-page":"363a","article-title":"Re-treatment with a rituximab based therapy is highly effective in autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia (CLL)","volume":"98","author":"Gupta","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB97","first-page":"339a","article-title":"Fludarabine synergises with anti-CD20 monoclonal antibody Rituximab in complement mediated cell lysis","volume":"96","author":"Golay","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB98","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/(SICI)1097-0215(20000101)85:1<104::AID-IJC19>3.0.CO;2-G","article-title":"Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas","volume":"85","author":"Johnson","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.leukres.2003.08.017_BIB99","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1046\/j.1365-2141.2001.03014.x","article-title":"Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone","volume":"114","author":"Di Gaetano","year":"2001","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB100","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB101","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","article-title":"Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukemia","volume":"15","author":"Osterborg","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB102","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1200\/JCO.2002.06.119","article-title":"Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine","volume":"20","author":"Rai","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB103","first-page":"603a","article-title":"Campath-1H therapy in 29 patients with refractory CLL: true complete remission is an attainable goal","volume":"94","author":"Kennedy","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB104","first-page":"365a","article-title":"Efficacy and safety of Almetuzumab (Campath-1H) in refractory B-CLL patients treated on a compassionate basis","volume":"98","author":"Rai","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB105","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/blood.V99.6.2245","article-title":"Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia","volume":"99","author":"Kennedy","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB106","first-page":"803a","article-title":"Development of a new, four-weekly schedule (Flucam) with concomitantapplication of Campath-1H and fludarabine in patients with relapsed\/refractory CLL","volume":"100","author":"Elter","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB107","first-page":"366a","article-title":"Incidence of cytomegalovirus (CMV) viremia during Campath-1H therapy for relapsed\/refractory chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL)","volume":"98","author":"Thai","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB108","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1053\/sonc.2002.30150","article-title":"Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia","volume":"29","author":"Nabhan","year":"2002","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB109","first-page":"365a","article-title":"Phase I study of Rituximab and Campath-1H in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"98","author":"Nabhan","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB110","doi-asserted-by":"crossref","unstructured":"Faderl S, Thomas DA, O\u2019Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003; 101(9):3413\u20133415.","DOI":"10.1182\/blood-2002-07-1952"},{"key":"10.1016\/j.leukres.2003.08.017_BIB111","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","article-title":"Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity","volume":"19","author":"Byrd","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB112","doi-asserted-by":"crossref","first-page":"466","DOI":"10.7326\/0003-4819-117-6-466","article-title":"Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone","volume":"117","author":"Anaissie","year":"1992","journal-title":"Ann. Intern. Med."},{"issue":"Suppl 1","key":"10.1016\/j.leukres.2003.08.017_BIB113","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1007\/s00282-997-0041-4","article-title":"Complications in the treatment of CLL with purine analogues","volume":"39","author":"Juliusson","year":"1997","journal-title":"Hematol. Cell Ther."},{"key":"10.1016\/j.leukres.2003.08.017_BIB114","first-page":"387a","article-title":"First line therapy of patients with advanced chronic lymphocytic leukemia (CLL) older than 65 years with fludarabine versus chlorambucil: interim analysis of a phase III study of the German CLL Study Group (GCLLSG)","volume":"100","author":"Schmitt","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB115","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood.V81.11.2878.2878","article-title":"Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent","volume":"81","author":"Keating","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB116","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1038\/sj.leu.2402216","article-title":"Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia","volume":"15","author":"Robak","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2003.08.017_BIB117","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1034\/j.1600-0609.2001.00303.x","article-title":"Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies","volume":"66","author":"Robak","year":"2001","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB118","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1182\/blood.V98.5.1326","article-title":"Rituximab therapy of patients with B-cell chronic lymphocytic leukemia","volume":"98","author":"Huhn","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.08.017_BIB119","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","article-title":"Rituximab dose-escalation trial in chronic lymphocytic leukemia","volume":"19","author":"O\u2019Brien","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB120","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin\u2019s lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2003.08.017_BIB121","first-page":"364a","article-title":"Single agent rituxan in early stage chronic lymphocytic leukemia (CLL)","volume":"98","author":"Thomas","year":"2001","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212603003151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212603003151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T23:29:48Z","timestamp":1623540588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212603003151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":121,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S0145212603003151"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2003.08.017","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}